Is Semaglutide or Tirzepatide Better for Weight Loss?

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Clinical trials show tirzepatide produces greater average weight loss than semaglutide across most patient populations. Both medications work through the GLP-1 system, but tirzepatide adds a second receptor target that may amplify appetite control and metabolic effects. Choosing between them depends on your medical history, genetic response profile, and weight loss goals.

How Semaglutide and Tirzepatide Work Differently

Semaglutide is a GLP-1 receptor agonist, meaning it mimics a single hormone that signals fullness and slows stomach emptying. This mechanism has proven effective for weight management and was originally developed for type 2 diabetes. Most patients experience reduced appetite within days of starting semaglutide, and the effect strengthens as dosing increases over weeks.

Tirzepatide is a GIP/GLP-1 receptor agonist, activating two distinct hormone pathways simultaneously. The dual-receptor approach addresses appetite suppression, metabolic rate, and glucose control through independent mechanisms. This combination creates what researchers call an additive or synergistic effect on weight loss and metabolic health markers.

Clinical Trial Results: Weight Loss Outcomes

Landmark tirzepatide trials (SURMOUNT-1 and SURMOUNT-2) demonstrated average weight loss of 20–22% of starting body weight over 72 weeks at maximum doses. Comparable semaglutide trials showed average weight loss of 12–15% over similar timelines. These differences held across multiple patient groups, though individual results vary significantly based on genetics, metabolism, and lifestyle factors.

The tirzepatide advantage became evident at equivalent time points and continued widening as dosing progressed. However, semaglutide's longer clinical history and lower tolerability burden make it suitable for many patients. Neither medication produces weight loss alone; both require consistent calorie awareness and movement as foundations for success.

Side Effects and Tolerability Considerations

Common semaglutide side effects include nausea, vomiting, constipation, and fatigue, typically mild and declining after the first 2–4 weeks. Most patients adjust well at standard starting doses, and side effects diminish as the body adapts. Gastrointestinal symptoms are the most frequent reason for pausing or stopping treatment.

Tirzepatide produces a similar side-effect profile but with higher reported rates of nausea during dose escalation phases. This occurs because two receptor pathways are being activated simultaneously, requiring careful dose titration. Some patients find tirzepatide's side effects manageable; others prefer semaglutide's gentler tolerance curve. PlexusDx support teams help monitor symptoms and adjust protocols accordingly.

Personalized Selection: Genetics and Medical History

Genetic variation in GIPR, FTO, and MC4R genes influences how individual bodies respond to these medications. Someone with specific genetic variants may lose significantly more weight on tirzepatide, while another person might respond equally well to semaglutide with fewer side effects. PlexusDx's Precision Peptide Genetic Test maps 14 pathways and 49 peptides across 150+ genetic insights to reveal your personalized response likelihood.

Medical history also shapes the choice: patients with diabetes may benefit more from tirzepatide's dual metabolic action, while those prioritizing gradual, steady weight loss might prefer semaglutide's established safety profile. Kidney or pancreatic concerns, prior GLP-1 use, and medication interactions all factor into the decision. PlexusDx clinicians review these factors during intake and may recommend starting with one medication, switching, or even exploring combination protocols like GLP-Squared.

Cost, Access, and PlexusDx Pricing

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan) flat, while compounded tirzepatide injection is $289/mo month-to-month, or from $249/mo on the 6-month plan flat. The pricing structure remains consistent regardless of dose escalation—your dose may need to go up, but your price won't. Both are manufactured by licensed 503A compounding pharmacies and ship to all 50 states without insurance or membership requirements.

Oral versions cost more due to formulation complexity: oral semaglutide is $289/mo month-to-month (or $249/mo on the 6-month plan), and oral tirzepatide at $349/mo (or $279/mo on the 6-month plan). For patients exploring both options, GLP-Squared Injection (combining semaglutide and tirzepatide) is $289/mo month-to-month (or $249/mo on the 3-month plan), offering a hybrid approach. HSA and FSA accounts cover all PlexusDx medications, and the Precision Peptide Genetic Test ($298) can help justify the tirzepatide investment by describing your pathway-level genetic baseline.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Will tirzepatide always produce more weight loss than semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

What is the difference between GLP-1 and GIP receptors?

GLP-1 receptors regulate appetite, stomach emptying, and blood sugar. GIP receptors influence metabolic rate, fat storage, and glucose control through separate pathways. Tirzepatide's dual activation produces complementary effects; semaglutide's single-pathway focus is proven effective but typically produces smaller overall weight loss.

Can I switch from semaglutide to tirzepatide?

Yes, many patients transition between them based on tolerance, cost, or response. PlexusDx supports switches by maintaining continuity of care and adjusting your treatment protocol. A brief washout period is typically unnecessary, though timing should be discussed with your PlexusDx clinician.

Are compounded semaglutide and tirzepatide as effective as brand-name versions?

PlexusDx compounded medications are manufactured by licensed 503A pharmacies to pharmaceutical standards and are bioequivalent to brand formulations. They are not FDA-approved as branded drugs, but compounding is legal and regulated. Efficacy is comparable because the active ingredient and pharmaceutical quality meet the same specifications.

How does the Precision Peptide Genetic Test help me choose between these medications?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Tirzepatide Vs Semaglutide For Weight Loss
• Semaglutide For Weight Loss 2
• Tirzepatide For Weight Loss 2
• Semaglutide Tablets For Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.